Company Overview of Synthetic Genomics, Inc.
Synthetic Genomics, Inc., a synthetic biology company, focuses on developing and commercializing genomic-driven solutions and products for various industries. The company focuses on various commercialization programs, including developing synthetic DNA products, tools, and instruments for organizations with demands for large and/or complex DNA constructs; algae based food and nutritional products, and biofuels; and synthetically-derived vaccines and anti-microbials. It is also developing clean water technologies using microbial fuel cells; and sustainable agricultural products, such as high-yielding, disease resistant, and economic plant feedstocks. The company has a strategic partnership wi...
11149 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2005
Key Executives for Synthetic Genomics, Inc.
Chief Executive Officer and Director
Co-Founder and Co-Chief Scientific Officer
Compensation as of Fiscal Year 2014.
Synthetic Genomics, Inc. Key Developments
Synthetic Genomics, Inc. Appoints Oliver Fetzer as Chief Executive Officer and Director
Oct 27 14
Synthetic Genomics, Inc. announced the appointment of Oliver Fetzer as a Chief Executive Officer (CEO). In his role as CEO, Fetzer will also be a member of SGI's Board of Directors. Dr. Fetzer will lead all aspects of SGI, including management of SGI's three business units--SGI-DNA, Synthetic Genomics Vaccines, Inc. (SGVI), and Genovia Bio. Dr. Fetzer comes to SGI from Cerulean Pharma Inc., where he was President and CEO for five years.
Avoca, Inc. Signs Supply Agreement with Synthetic Genomics, Inc. to Become Domestic Source of Natural Astaxanthin
Jun 20 14
Avoca, Inc. has formed a supply agreement with Synthetic Genomics, Inc. to extract and commercialize natural astaxanthin from a strain of algae developed by SGI. The multi-year supply agreement also provides Avoca with exclusivity for product sales in North America. Pharmachem Laboratories will be responsible for marketing and sales. SGI is developing this product through their Genovia Bio business unit, which is responsible for the development and commercialization of algal-based food, chemical and fuel products. Financial details were not disclosed. Natural astaxanthin is a supplement with multiple clinically-proven health benefits associated with its powerful antioxidant and anti-inflammatory properties. Natural astaxanthin is very difficult to produce and therefore supply constrained relative to demand. SGI has developed a process for production of natural astaxanthin from a phototrophic source and demonstrated commercial-scale manufacturing capability and performance over 18 months. SGI's natural astaxanthin has U.S. Food and Drug Administration regulatory approval for dietary supplement applications.
Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc. to Develop Humanized Pig Organs to Revolutionize Transplantation Field
May 6 14
Synthetic Genomics Inc. and Lung Biotechnology Inc. announced they have entered into a multi-year research and development agreement to develop humanized pig organs using synthetic genomic advances. The collaboration will focus upon developing organs for human patients in need of transplantation, with an initial focus on lung diseases. As part of the agreement SGI will receive royalties and milestone incentives from the development and commercialization of the organs. Using unique DNA design, DNA synthesis and genome editing, as well as genome modification tools, SGI will develop engineered primary pig cells with modified genomes. This work will entail modification of a substantial number of genes at an unprecedented scale and efficiency. United Therapeutics will leverage its xenotransplantation expertise to implant these engineered cells, generating pig embryos which develop and are born with humanized lungs. With the science and technology advances made by the SGI team in recent years, the companies are striving to develop these new methods and advances to create organs that are safe and effective for use in humans.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 6, 2014